Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?

Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?

Background: Circulating tumor cell (CTC) counting may be a useful non-invasive biomarker that helps patients choose first-line treatment options. Nevertheless, the cost of CTC inspection may impose an economic burden on patients, necessitating the simultaneous consideration of both its clinical effe...

Full description

Bibliographic Details
Main Authors: Huiting Lin, Wenhua Wu, Xiaoya Lou, Yiming Wang, Hong Sun, Jiaqin Cai, Suyan Liu, Xiaoxia Wei
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Breast
Subjects:
Circulating tumor cell
Cost-effectiveness analysis
Breast cancer
Markov model
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977624000110

Internet

http://www.sciencedirect.com/science/article/pii/S0960977624000110

Similar Items